Introduction to GLP-1 Receptor Agonists

Module Description

GLP-1 receptor agonists represent an important class of glucose-lowering therapies. As a class, GLP-1 receptor agonists have robust glucose-lowering effects, promote weight loss, have a low risk for contributing to hypoglycemia, and are recommended in people with type 2 diabetes with risk factors or established atherosclerotic cardiovascular disease to mitigate cardiovascular risk. Important counseling points to help patients minimize side effects and maximize benefits will be provided.

Learning Objectives

At the end of this module, participants will be able to:

Recognize the potential benefits of GLP-1 receptor agonist therapy in people with type 2 diabetes (T2D).
Recall the role of GLP-1 receptor agonists in mitigating cardiovascular risk.
Identify key safety and tolerability considerations when initiating GLP-1 receptor agonist therapy in a person with T2D and strategies for risk mitigation.

Module Faculty

Joshua Neumiller, PharmD, CDCES, FADCES, FASCP

Joshua Neumiller, PharmD, CDCES, FADCES, FASCP, is Vice-Chair and Allen I. White Distinguished Professor at Washington State University. Dr. Neumiller is a clinical pharmacist and a certified diabetes care and education specialist (CDCES). He works as a consultant pharmacist in the home health setting and holds a research appointment with Providence Medical Research Center (PMRC). Dr. Neumiller has authored or co-authored several ADA books and is past Chair of the ADA’s Professional Practice Committee, the committee responsible for updating the ADA’s Standards of Care in Diabetes each year.

Course Support

If you have questions about this course, please email walmartlearning@diabetes.org .

Summary


Availability:	Retired


Credit Offered:	No Credit Offered

Create Account